期刊
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
卷 56, 期 5, 页码 2493-2503出版社
AMER SOC MICROBIOLOGY
DOI: 10.1128/AAC.06305-11
关键词
-
资金
- Novartis Pharmaceuticals
The in vitro activities of LFF571, a novel analog of GE2270A that inhibits bacterial growth by binding with high affinity for protein synthesis elongation factor Tu, fidaxomicin, and 10 other antimicrobial agents were determined against 50 strains of Clostridium difficile and 630 other anaerobic and aerobic organisms of intestinal origin. LFF571 possesses potent activity against C. difficile and most other Gram-positive anaerobes (MIC90, <= 0.25 mu g/ml), with the exception of bifidobacteria and lactobacilli. The MIC(90)s for aerobes, including enterococci, Staphylococcus aureus (as well as methicillin-resistant S. aureus [MRSA] isolates), Streptococcus pyogenes, and other streptococci were 0.06, 0.125, 2, and 8 mu g/ml, respectively. Comparatively, fidaxomicin showed variable activity against Gram-positive organisms: MIC(90)s against C. difficile, Clostridium perfringens, and Bifidobacterium spp. were 0.5, <= 0.015, and 0.125 mu g/ml, respectively, but >32 mu g/ml against Clostridium ramosum and Clostridium innocuum. MIC90 for S. pyogenes and other streptococci was 16 and >32 mu g/ml, respectively. LFF571 and fidaxomicin were generally less active against Gram-negative anaerobes.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据